NEWS

• Tamoxifen improves breast cancer survival in older women  (Reuters)
  Among breast cancer patients, women in their 60s, post-menauposal who had no sign of cancer spread had the lowest cancer recurrence rates and the highest survival rates, according to results of a UK study. Jan 14, 2000
• Lumpectomy surgery may not remove enough breast tissue  (Reuters)
  Younger women with noninvasive breast cancer who have had a lumpectomy appear to be at greater risk for recurrence of the cancer than older, post-menauposal patients are, US researchers report. Jan 19, 2000
  
• Pharmacia & Upjohn Launches AROMASIN(R) (exemestane tablets) - A New Breast Cancer Treatment For Women Who Experience Failure on Tamoxifen  (PR Newswire)
  Pharmacia & Upjohn today announced the availability of AROMASIN(R), the first oral aromatase inactivator for the treatment of postmenopausal women with advanced breast cancer whose tumors stop responding to tamoxifen therapy. Jan 21, 2000
• Hormone Combination May Pose Risk  (Associated Press)
  Menopausal women using the common hormone supplements estrogen and progestin run a 20 percent higher risk of breast cancer than those who use just estrogen, researchers reported today. JAMA - Jan 26, 2000.
• REPORT: No Implants-Illness Link Found  (Associated Press)
  Silicone breast implants do not cause major illnesses yet they frequently break open and leak, which can cause pain, disfigurement and repeat surgery, concludes a long-awaited report that says women must be forewarned about breakage.
  
• REPORT: Soy supplements fail to help menopause symptoms / Abstract: Pacific Coast reproductive Society / Hochanadel et al: April 99 Meeting

• REPORT: SHARK Cartilage is shown to be ineffective in the advanced carcinoma - J Clin Onc 1998;16:3649-3655

• TUESDAY OCT 29, 1998: FDA Release: Tamoxifen has been approved for healthy women with high risk factors for breast cancer (based on the NSABBP study which showed a remarkable 44% risk reduction of developing breast cancer).

• NEW ENGLAND JOURNAL OF MEDICINE: Several good articles are exposing the Pros and Cons of the Sentinel Lymphadenectomy in the management of patients with breast cancers.The New England Journal of Medicine 1998;339:941-946, 990-995.

• FDA RELEASE: The US FDA approved a bioengineered antibody - HERCEPTIN (Genentech)-   in the treatment of advanced breast cancer..

• REPORT: Mohammed S. et al: Better survival in familial breast cancer [Brit. J. Of Cancer: 1998-77-2252-2255]

• REPORT: Veronesi et al:: Sentinel Lymphadenectomy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. This study confirms that sentinel lymphadenectomy is an effective staging option. [ THE LANCET: 97,349,9069,1864]

• REPORT: EVISTA® or Raloxifene (estrogen receptor modulator) used to prevent osteoporosis in post-menauposal women may also reduce their risk of breast cancer by almost 70%. Preliminary findings [ AM SOC of CLINICAL ONCOLOGY CONVENTION - MAY 1998)

• REPORT ----- HERCEPTIN® This drug is the first genetically engineered drug showing promise in the gene-based treatment for  some form of metastatic (+Her2 Neu) breast cancer. [ AM SOC of CLINICAL ONCOLOGY CONVENTION - MAY 1998)

FIBRIJET™ SURGICAL SEALANT DELIVERY SYSTEMS

FOR FORMAL AXILLARY LYMPHADENECTOMIES